Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Inclusion Criteria:

   - For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required
   diagnostic bone marrow sample has been fulfilled

      - For patients who have not previously enrolled on APEC14B1 prior to enrollment on
      AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if
      marrow sample unavailable) must be available to develop an MRD probe

      - In addition, laboratory reports detailing evidence of BCR-ABL1 fusion or
      ABL-class fusion must be submitted for rapid central review within 72 hours of
      study enrollment

   - >= 1 year (365 days) and =< 21 years at ALL diagnosis

   - Ph+ (BCR-ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed
   phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO]
   definition) with definitive evidence of BCR-ABL1 fusion by karyotype, fluorescence in
   situ hybridization (FISH) and/or molecular methodologies

   - ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions.
   ABL-class fusions are defined as those involving the following genes: ABL1, ABL2,
   CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization
   (FISH, e.g. using break-apart or colocalization signals probes), multiplex or
   singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole
   transcriptome or panel-based ribonucleic acid (RNA)-sequencing (e.g. TruSight RNA
   Pan-Cancer Panel; Illumina, San Diego, CA, USA or similar)

   - Ph+ patients must have previously started Induction therapy, which includes
   vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or
   other standard cytotoxic chemotherapy

   - Ph+ patients have not received more than 14 days of multiagent Induction therapy
   beginning with the first dose of vinCRIStine

   - Ph+ patients may have started imatinib prior to study entry but have not received more
   than 14 days of imatinib

   - ABL-class fusion patients must have previously completed the 4 or 5 weeks of
   multiagent Induction chemotherapy (Induction IA phase)

   - ABL-class fusion patients may have started imatinib during Induction IA, at the same
   time of or after the first vinCRIStine dose

   - Patients must have a performance status corresponding to Eastern Cooperative Oncology
   Group (ECOG) scores of 0, 1, or 2

   - Direct bilirubin =< 2.0 mg/dL

   - Shortening fraction of >= 27% by echocardiogram

   - Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram

   - Corrected QT interval, QTc < 480 msec

      - Note: Repeat echocardiogram and electrocardiogram are not required if they were
      performed at or after initial ALL diagnosis, before study enrollment

   - Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
   mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as
   follows:

      - 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)

      - 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)

      - 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)

      - 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)

      - 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)

      - >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

Exclusion Criteria:

   - Known history of chronic myelogenous leukemia (CML)

   - ALL developing after a previous cancer treated with cytotoxic chemotherapy

   - Active, uncontrolled infection, or active systemic illness that requires ongoing
   vasopressor support or mechanical ventilation

   - Down syndrome

   - Pregnancy and breast feeding

      - Female patients who are pregnant since fetal toxicities and teratogenic effects
      have been noted for several of the study drugs; a pregnancy test is required for
      female patients of childbearing potential

      - Lactating females who plan to breastfeed their infants

      - Sexually active patients of reproductive potential who have not agreed to use an
      effective contraceptive method for the duration of treatment according to
      protocol

   - Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart
   block

   - Prior treatment with dasatinib, or any TKI other than imatinib